London 4th May 2017 –
GTN Ltd today announced it has raised £2.1 million ($3 million) of seed funding in the UK, led by Octopus Ventures and Pentech with participation from existing investor Entrepreneur First. This funding will support GTN’s mission to transform drug discovery through interdisciplinary innovation.
“GTN uniquely combines multiple scientific disciplines, including quantum physics, biochemistry and deep learning to revolutionise medicine discovery,” said Professor Noor Shaker, Co-Founder and CEO of GTN.
The London-based company’s technology already outperforms state of the art machine learning models in predicting molecular properties such as binding energy and toxicity. GTN is currently running collaborations with global Pharmaceutical companies and also has strong partnerships with world-leading research bodies including the Francis Crick Institute.
Sandy McKinnon, Partner at Pentech has said “GTN is turning serendipitous drug discovery into engineered drug design through advancing the state of the art in computational chemistry. They could be hugely enabling and disruptive to the Pharma industry.”
GTN is currently recruiting for a number of roles within the Machine Learning, Computational Chemistry and Drug Discovery fields.